Selected accession A0A3Q2HDT6; ordinary UniProt record is TrEMBL and cites genome sequencing/submission rather than a gene-specific functional experiment. Human evidence is summarized in the paired human investigation. Sequence comparison records the exact target gaps and transfer limits. The targeted Europe PMC search found no decisive gene-specific horse functional assay warranting a separate horse Edison investigation; general omics/association hits were not counted as mechanistic validation.
The 1999 discovery study observed negligible autophosphorylation yet restoration of an IL-1 response in IRAK-deficient cells. The 2002 genetic study established physiological negative regulation: IRAK-M prevents IRAK/IRAK4 release from MyD88 and restricts cytokine induction and endotoxin sensitivity. The 2021 human structure explains a noncanonical inactive catalytic site, a distinctive homodimer and a possible IRAK4-interaction surface. ATP-pocket retention or weak nucleotide binding cannot establish active kinase catalysis. The positive cell-reconstitution result and inhibitory physiological feedback should coexist in the synthesis rather than being flattened into an unconditional activator or inhibitor. The selected horse N-terminal deletion reaches its death-domain start, so receptor-complex assembly needs specific checking.
Sources: PMID:10383454(https://pubmed.ncbi.nlm.nih.gov/10383454/), PMID:12150927(https://pubmed.ncbi.nlm.nih.gov/12150927/), PMID:33238146(https://pubmed.ncbi.nlm.nih.gov/33238146/).
The published human IRAK3 CGS291–293 and DFA311–313 motifs map to horse CGS249–251 and DFA269–271 in the frozen UniProt sequences. This supports conservation of the noncanonical pseudokinase configuration. It does not establish that the shortened horse N-terminal interaction region assembles normally, nor exclude every alternative catalytic mechanism. Primary structural study; computed mapping; reproduction script.